Table 1 Baseline demographic and clinical characteristics
From: High-sensitivity C-reactive protein level in stable-state bronchiectasis predicts exacerbation risk
Whole cohort (n = 123) | No exacerbation on follow-up (n = 97) | Exacerbation on follow-up (n = 26) | P-values | |
|---|---|---|---|---|
Age (years), mean ± SD | 68.5 ± 11.2 | 68.7 ± 10.4 | 67.9 ± 14.0 | 0.395 |
Male | 43 (35.0%) | 30 (30.9%) | 13 (50.0%) | 0.070 |
Smoking status | 0.833 | |||
Current smoker | 4 (3.3%) | 3 (3.1%) | 1 (3.8%) | |
Ex-smoker | 15 (12.2%) | 11 (11.3%) | 4 (15.4%) | |
Non-smoker | 104 (84.6%) | 83 (85.6%) | 21 (80.8%) | |
FEV1 (L), mean ± SD | 1.71 ± 0.64 | 1.69 ± 0.60 | 1.79 ± 0.76 | 0.303 |
FEV1 (% predicted) mean ± SD | 87.3 ± 23.2 | 90.0 ± 22.8 | 78.0 ± 22.9 | 0.019* |
FEV1/FVC ratio (%), mean ± SD | 68.8 ± 11.9 | 69.4 ± 11.4 | 66.6 ± 13.6 | 0.190 |
mMRC dyspnea scale | 0.308 | |||
0 | 27 (22.0%) | 24 (24.7%) | 3 (11.5%) | |
1 | 45 (36.6%) | 35 (36.1%) | 10 (38.5%) | |
2 | 39 (31.7%) | 31 (32.0%) | 8 (30.8%) | |
3 | 10 (8.1%) | 6 (6.2%) | 4 (15.4%) | |
4 | 2 (1.6%) | 1 (1.0%) | 1 (3.8%) | |
Extent of involvement ≥ 3 lobes | 48 (39.0%) | 35 (36.1%) | 13 (50.0%) | 0.196 |
Pseudomonas aeruginosa colonization | 44 (35.8%) | 29 (29.9%) | 15 (57.7%) | 0.009* |
hs-CRP (mg/dL), mean ± SD | 0.37 ± 0.64 | 0.28 ± 0.44 | 0.71 ± 1.04 | 0.026* |
E-FACED score, median [IQR] | 2 [0.5–3] | 2 [0–3] | 0.158 |